For some, perhaps getting patents in India just isn’t worth the hassle anymore

Roche announced last week that it is allowing the Indian patent covering its breast cancer treatment Trastuzumab – marketed under the brand name of Herceptin – to expire. If other life sciences companies follow suit and decide that Indian patents…

Get unlimited access to all IAM content